Chugai Pharmaceutical (4519) Stock Price, Fundamentals & Analysis

What 4519 does

Chugai Pharmaceutical (4519) is a stock listed on the Tokyo Stock Exchange in the Healthcare sector, specifically in the Drug Manufacturers - General industry. The company researches, develops, manufactures, and sells pharmaceuticals in Japan and internationally. Its portfolio includes oncology treatments such as Alecensa, Avastin, Herceptin, Kadcyla, and Tecentriq, along with products like Actemra, CellCept, Tamiflu, and Hemlibra. Chugai Pharmaceutical also collaborates with Phylo, Inc. to apply an agentic AI platform to its drug discovery process. The company was formerly known as Chugai Shinyaku Shokai and adopted its current name in January 1943. In the broader Japanese healthcare landscape, it operates alongside peers such as Terumo (4543), Daiichi Sankyō (4568), and Takeda Pharmaceutical (4502).

Key numbers explained

• Price (6,616 JPY): The last traded price of one share. A negative price change today of -0.51% indicates a slight decline on the current trading day.
• Market cap (10.89T JPY): The total market value of all outstanding shares, calculated as share price multiplied by the number of shares. It is a measure of the company's overall size.
• Trailing P/E ratio (23.1): This price-to-earnings ratio divides the current share price by the trailing 12-month earnings per share (286.47 JPY). It shows how much investors are paying for each unit of recent earnings.
• Forward P/E ratio (28): Similar to the trailing P/E, but based on expected future earnings. It reflects market expectations about growth.
• Dividend yield (2%): This dividend yield represents the annual dividend payment as a percentage of the share price. The exDividendDate is Dec 29, 2026, and 48% of earnings are paid out as dividends.
• Beta (0.55): A measure of the stock's volatility relative to the overall market. A beta below 1 suggests the stock is less volatile than the market.
• Revenue growth (17.8% year over year): The rate at which the company's top line has grown over the trailing 12 months, with revenue at 1.34T JPY.
• Price change over the last 52 weeks (4.7%): The total return from the price one year ago to the current price, within a 52-week range of 6,284 – 10,700.

What to watch

For Chugai Pharmaceutical (4519), several general factors can influence its performance. As a healthcare stock, it is sensitive to drug approval cycles, patent expirations, and regulatory changes in Japan and international markets. The company's heavy focus on oncology means it is closely watched for clinical trial results and new product launches. Its relatively low beta of 0.55 suggests it may be less reactive to broad market swings, which is a characteristic often sought in defensive sectors. Investors tracking the Japanese market may also compare it with other large-cap healthcare names like Astellas (4503) or Olympus (7733). The upcoming nextEarningsDate of Oct 27, 2026 is a key date for reviewing the company's financial trajectory.